Evaluation of the Influence of Food Regimen on Oshadi D Absorption

NCT ID: NCT01327352

Last Updated: 2012-06-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-04-30
• Study Completion Date: 2011-10-31

Brief Summary

The study will be a non-randomized, open label, single dose, placebo control, single center, and single arm study in healthy subjects. The study will include one administration of placebo and four single administrations of Oshadi D in two different dose levels, administered in two feeding regimen for the evaluation of the influence of food on Oshadi D absorption.

Conditions

Lupus Erythematosus, Systemic

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Blinding Strategy: NONE

Study Groups

Oshadi D

2 dose levels of Oshadi D in 2 food regimen will be administered as following:

• Subjects will receive placebo on the morning of day 1 during fast. Late breakfast will be provided 4 hours following placebo administration.
• On day 8 a single dose of 180mg Oshadi D will be administrated during fast. Late breakfast will be provided 4 hours following drug administration
• On day 16 subjects will be administered with 360mg of Oshadi D during fast. Late breakfast will be provided 4 hours following drug administration.
• On day 24, 180mg of Oshadi D will be administrated immediately after breakfast.
• On day 32, subject will be administered with 360mg of Oshadi immediately after breakfast.

Group Type: EXPERIMENTAL

Oshadi D

Intervention Type: DRUG

oral administration

Interventions

Oshadi D

oral administration

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy Male/female 21 years old and up.
• Subject must understand and be willing to give written informed consent prior to any study procedures or evaluations and be willing to adhere to all study schedules and requirements.
• Subject must be sterile or infertile or use an approved method of contraception from the time that the first dose of study medication is taken until three months following study completion or discontinuation.

Exclusion Criteria

• Any history of significant cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic hepatic disease or any other disease which in the judgment of the investigator would interfere with the study or confound the results.
• Subject with positive HIV serology or positive HBsAg at screening.
• History or evidence of any active liver disease.
• Female subject who are breastfeeding or have a positive pregnancy test at screening or at any time during the study.
• Inability to give written informed consent
• History of alcohol or drug abuse within 6 months of screening.
• Subject who have a positive urine drug screen for substances of abuse (benzodiazepine, THC, opiates, amphetamines, cocaine) at the screening.
• Mental disorders.
• Subject with poor venous access
• Significant swallowing disorders
• Digestive disorders;
• Small bowel surgery;
• Mall absorption disorders.

• Minimum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Oshadi Drug Administration

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Keren Duanis, MD

Role: PRINCIPAL_INVESTIGATOR

Assaf Harofe Medical Center, Israel

Hanna Levy, Dr.

Role: STUDY_DIRECTOR

Oshadi Drug Administration

Locations

Assaf Harofe Medical Center,

Zrifin, , Israel

Countries

Israel

Other Identifiers

OS-DN-P1b-01

Identifier Type: -

Identifier Source: org_study_id